Discovery	O
and	O
characterization	O
of	O
super	O
-	O
enhancer	O
-	O
associated	O
dependencies	O
in	O
diffuse	B-DISEASE
large	I-DISEASE
B	I-DISEASE
cell	I-DISEASE
lymphoma	E-DISEASE
.	O
Diffuse	B-DISEASE
large	I-DISEASE
B	I-DISEASE
cell	I-DISEASE
lymphoma	E-DISEASE
(	O
DLBCL	S-DISEASE
)	O
is	O
a	O
biologically	O
heterogeneous	O
and	O
clinically	O
aggressive	O
disease	O
.	O


Here	O
,	O
we	O
explore	O
the	O
role	O
of	O
bromodomain	O
and	O
extra	O
-	O
terminal	O
domain	O
(	O
BET	O
)	O
proteins	O
in	O
DLBCL	S-DISEASE
,	O
using	O
integrative	O
chemical	O
genetics	O
and	O
functional	O
epigenomics	O
.	O


We	O
observe	O
highly	O
asymmetric	O
loading	O
of	O
bromodomain	O
4	O
(	O
BRD4	O
)	O
at	O
enhancers	O
,	O
with	O
approximately	O
33	O
%	O
of	O
all	O
BRD4	O
localizing	O
to	O
enhancers	O
at	O
1	O
.	O
6	O
%	O
of	O
occupied	O
genes	O
.	O


These	O
super	O
-	O
enhancers	O
prove	O
particularly	O
sensitive	O
to	O
bromodomain	O
inhibition	O
,	O
explaining	O
the	O
selective	O
effect	O
of	O
BET	O
inhibitors	O
on	O
oncogenic	O
and	O
lineage	O
-	O
specific	O
transcriptional	O
circuits	O
.	O


Functional	O
study	O
of	O
genes	O
marked	O
by	O
super	O
-	O
enhancers	O
identifies	O
DLBCLs	S-DISEASE
dependent	O
on	O
OCA	O
-	O
B	O
and	O
suggests	O
a	O
strategy	O
for	O
discovering	O
unrecognized	O
cancer	S-DISEASE
dependencies	O
.	O


Translational	O
studies	O
performed	O
on	O
a	O
comprehensive	O
panel	O
of	O
DLBCLs	S-DISEASE
establish	O
a	O
therapeutic	O
rationale	O
for	O
evaluating	O
BET	O
inhibitors	O
in	O
this	O
disease	O
.	O
